Morphological response on mesenteric mass of small intestinal neuroendocrine tumors treated by 177Lu-DOTATATE: MESENLUTH – A GTE-ENDOCAN study

#3710

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) often metastasize, especially to mesenteric lymph nodes, which are frequently affected by fibrosis reactions due to local serotonin secretion. Peptide receptor radionuclide therapy (PRRT) with177Lu-Dotatate has shown its efficacy in the treatment of progressive SI-NETs.

Aim(s): However, due to specific tissue characteristics of desmoplastic mesenteric metastases, we can hypothesize that these lesions may be particularly refractory to PRRT.

Materials and methods: In this national retrospective multicentric study, we analysed the medical records of patients presenting SI-NET associated with metastatic mesenteric mass (MM). Inclusion criteria were patients having a histologically confirmed SI-NET, who have received at least one course of PRRT (177Lu) and have an available morphological evaluation. The primary end point was the morphologic response according to radiological criteria RECIST 1.1 on MM of SI-NET to 177Lu-Dotatate PRRT. We also evaluated the safety of PPRT on MM and clinical efficacy in patients with MM-related symptoms.

Conference:

Presenting Author: Walter T

Authors: Al Mansour L, de Mestier L, Haissaguerre M, Afchain P, Hadoux J,

Keywords: neuroendocrine tumor, mesenteric mass, objective response, 177Lu-DOTATATE,